This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Taltz
  • /
  • A Study of Ixekizumab (LY2439821) in Participants ...
Clinical trial

A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis (SPIRIT-P2)

Read time: 2 mins
Last updated:1st Dec 2014
Identifier: NCT02349295

The main purpose of this study is to evaluate how effective and safe the study drug known as ixekizumab is in participants with active psoriatic arthritis.

Study Type: Interventional
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Estimated Enrollment: 360
Study Start Date: December 2014
Estimated Study Completion Date: June 2019
Primary Completion Date: September 2016 (Final data collection date for primary outcome measure)

- Experimental:
Ixekizumab Dosing Regimen 1
- Experimental: Ixekizumab Dosing Regimen 2
- Placebo Comparator: Placebo

Category Value
Date last updated at source 2017-10-12
Study type(s) Interventional
Expected enrolment 360
Study start date 2014-12-01
Estimated primary completion date 2016-09-01

View full details